Open Access. Powered by Scholars. Published by Universities.®
- Discipline
-
- Cell Biology (2)
- Cell and Developmental Biology (2)
- Enzymes and Coenzymes (2)
- Life Sciences (2)
- Medical Biotechnology (2)
-
- Medical Sciences (2)
- Analytical, Diagnostic and Therapeutic Techniques and Equipment (1)
- Anatomy (1)
- Biochemistry (1)
- Biochemistry, Biophysics, and Structural Biology (1)
- Biology (1)
- Cancer Biology (1)
- Cardiovascular System (1)
- Diagnosis (1)
- Diseases (1)
- Genetic Phenomena (1)
- Hemic and Immune Systems (1)
- Hemic and Lymphatic Diseases (1)
- Immunology and Infectious Disease (1)
- Immunopathology (1)
- Laboratory and Basic Science Research (1)
- Medical Molecular Biology (1)
- Medicinal Chemistry and Pharmaceutics (1)
- Nucleic Acids, Nucleotides, and Nucleosides (1)
- Other Chemicals and Drugs (1)
- Pharmacology (1)
- Pharmacology, Toxicology and Environmental Health (1)
- Keyword
-
- AS1949490 (1)
- Angiogenesis (1)
- Breast cancer (1)
- Cancer (1)
- Cancer Survivorship (1)
-
- Endothelial Cell Biology (1)
- Glycolysis (1)
- HIF-1a (1)
- Hypoxia (1)
- INPPL1 (1)
- Lymphangiogenesis (1)
- Lymphatic System (1)
- Lymphedema (1)
- MAPK/ERK (1)
- Metabolism (1)
- MiRNAs (1)
- Near Infrared Fluorescence Imaging (1)
- Next Generation Sequencing (1)
- PI3K/AKT (1)
- SHIP2 (1)
- Small Molecule (1)
- Small molecules (1)
- Therapeutics (1)
- Warburg Effect (1)
Articles 1 - 3 of 3
Full-Text Articles in Chemicals and Drugs
Targeting Oncogenic Mirnas With Small Molecules For Breast Cancer Therapy, Paloma Del C. Monroig
Targeting Oncogenic Mirnas With Small Molecules For Breast Cancer Therapy, Paloma Del C. Monroig
Dissertations & Theses (Open Access)
The crucial role of microRNAs (miRNAs) in cancer pathobiology has driven the introduction of new drug development approaches such as miRNA inhibition. In order to advance miRNA-therapeutics, there is a need to develop screening strategies that can target tumors in a specific way. Small molecule inhibitors represent an attractive approach to pursue this. However, the absence of molecular structures for most of the miRNAs makes it very difficult to predict which inhibitors can bind to them. Herein we designed a strategy to screen for small molecules by assesing whether they could directly bind/ interact with miR-10b/miR-21. As part of our …
Normal Glycolytic Enzyme Activity Is Critical For Hypoxia Inducible Factor-1a Activity And Provides Novel Targets For Inhibiting Tumor Growth, Geoffrey Grandjean Phd
Normal Glycolytic Enzyme Activity Is Critical For Hypoxia Inducible Factor-1a Activity And Provides Novel Targets For Inhibiting Tumor Growth, Geoffrey Grandjean Phd
Dissertations & Theses (Open Access)
Normal Glycolytic Enzyme Activity is Critical for Hypoxia Inducible Factor-1α Activity and Provides Novel Targets for Inhibiting Tumor Growth
By Geoffrey Grandjean
Advisory Professor: Garth Powis, D. Phil
Unique to proliferating cancer cells is the observation that their increased need for energy is provided by a high rate of glycolysis followed by lactic acid fermentation in a process known as the Warburg Effect, a process many times less efficient than oxidative phosphorylation employed by normal cells to satisfy a similar energy demand [1]. This high rate of glycolysis occurs regardless of the concentration of oxygen in the cell and …
Src Homology 2 Domain-Containing 5’-Inositol Phosphatase-2 (Ship2) Is An Effector Of Lymphatic Dysfunction, Germaine D. Agollah
Src Homology 2 Domain-Containing 5’-Inositol Phosphatase-2 (Ship2) Is An Effector Of Lymphatic Dysfunction, Germaine D. Agollah
Dissertations & Theses (Open Access)
The lymphatic system is essential for the transport of excess fluid, protein, and foreign materials from interstitial tissues to lymph nodes; for immune surveillance, and to maintain fluid homeostasis. Dysregulated lymphatics can be attributed to pathological conditions including tumor metastasis, inflammation, chronic wounds, obesity, blood vascular disorders, and lymphedema. Of these, lymphedema is the most extreme of lymphatic disorders and is represented by a spectrum of symptoms ranging from mild, subtle presentation to severe, disfiguring, overt presentation. Lymphedema is more manageable in the early stages of disease but severely reduces quality of life with progression. Due to lack of molecular …